Results for the First Quarter 2018

Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…

Read more

Results for the Third Quarter 2017

Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…

Read more

Results for the Second Quarter 2017

Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

Read more

Results for the First Quarter 2017

Sales in the first quarter amounted to MNOK 74.4 (MNOK 65.5), a 13.5 % growth. Currency neutral growth of own products was 20.3 %. Sales from the US increases with 9.6 % in USD. In…

Read more

Results for the Fourth Quarter 2016

Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

Read more

Medistim Establishes Own Subsidiary in Spain

Annually, around 7.000 coronary artery bypass surgery (CABG) procedures and 8.000 vascular procedures are performed throughout the 56 cardiac centers and 75 vascular centers in Spain. Medistim currently has an installed base of 80 systems,…

Read more